Interleukin-7 and Interleukin-15 for Cancer

Lampaki, Sofia; Yarmus, Lonny; Kioumis, Ioannis; Pitsiou, Georgia; Katsikogiannis, Nikolaos; Hohenforst-Schmidt, Wolfgang; Li, Qiang; Huang, Haidong; Sakkas, Antonios; Organtzis, John; Sakkas, Leonidas; Mpoukovinas, Ioannis; Tsakiridis, Kosmas; Lazaridis, George; Syrigos, Konstantinos; Zarogoulidis, Konstantinos

doi:10.7150/jca.10471

Cited by 39 publications

(38 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, in humans, recombinant IL-7 has shown high potential for the treatment of lymphopenia occurring as a result of HIV infection or chemotherapy as IL-7 elicits a selective increase in non-T-regulatory CD4 + T cells [34]. However, IL-7 has also been shown to be produced by solid tumors and has been associated with a poor prognosis in breast cancer, bone metastatic disease, and hematological malignancies [33,38,39]. In our current study, it is unclear whether the decrease in IL-7 by vemurafenib treatment may normalize the TME with an antitumor effect or result in immune suppression and reduction of lymphocytes.…”

Section: Discussionmentioning

confidence: 97%

“…IL-7 is a potent proinflammatory cytokine that is produced by stromal cells as well as by dendritic cells, macrophages, neurons, and endothelial cells [33,34]. Systemic treatment with IL-7 in combination with other cytokines (IFNγ, IL-2, GMCSF) as immunotherapy has been studied in a number of animal tumor models [35][36][37], and has shown antitumor effects.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells

et al. 2016

View full text Add to dashboard Cite

The advent of drugs targeting the mitogen-activated protein kinase (MAPK) pathway has markedly changed the treatment of advanced-stage melanoma harboring BRAF mutations. However, drug resistance, through mechanisms not well elucidated, often occurs. A better understanding of how melanoma-derived immunologically active molecules change in response to MAPK inhibition of BRAF mutated (BRAF) and BRAF wild type (BRAF) melanomas could help identify promising treatment combinations of small molecule inhibitors and immunotherapy. To this aim, we treated 13 BRAF and 13 BRAF mutated human melanoma cell lines with either a specific BRAF inhibitor or an MEK1/2 inhibitor and analyzed changes in the secretion of 42 selected cytokines, chemokines, and growth factors. We also measured changes in the expression levels of immunologically relevant melanoma cell surface markers. The BRAF melanomas showed minimal changes in response to the inhibitors, whereas the BRAF cell lines showed, on average, a significant decrease in IFNα2, interleukin-7, Fractalkine, GCSF, GRO, TGFα2, interleukin-8, and VEGF, as well as a reduction in pERK and pMEK protein levels, upon MAPK pathway blockade. BRAF inhibition in BRAF cell lines also resulted in significant changes in the expression of several surface markers including upregulation of β2-microglobulin as well as a decrease in MIC A/B and TRAIL-R2. These results indicate that MAPK pathway inhibition leads to changes in the immunological properties of mutant BRAF melanoma cells and lends support for future studies aimed at designing effective treatment strategies that combine BRAF and MEK inhibition with immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Interestingly, control samples did not secrete IL-7. IL-7 is considered a powerful pro-inflammatory cytokine, which can induce tumorigenesis [59]. A variety of cells, for example intestinal epithelial cells, keratinocytes, hepatic tissue, endothelial cells, smooth muscle cells, fibroblasts, thyroid cancer cells and others, have proven to produce IL-7 [21, 60].…”

Section: Discussionmentioning

confidence: 99%

Cytokine Release and Focal Adhesion Proteins in Normal Thyroid Cells Cultured on the Random Positioning Machine

Warnke

Pietsch

Kopp

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Spaceflight impacts on the function of the thyroid gland in vivo. In vitro normal and malignant thyrocytes assemble in part to multicellular spheroids (MCS) after exposure to the random positioning machine (RPM), while a number of cells remain adherent (AD). We aim to elucidate possible differences between AD and MCS cells compared to 1g-controls of normal human thyroid cells. Methods: Cells of the human follicular epithelial thyroid cell line Nthy-ori 3-1 were incubated for up to 72 h on the RPM. Afterwards, they were investigated by phase-contrast microscopy, quantitative real-time PCR and by determination of cytokines released in their supernatants. Results: A significant up-regulation of IL6, IL8 and CCL2 gene expression was found after a 4h RPM-exposure, when the whole population was still growing adherently. MCS and AD cells were detected after 24 h on the RPM. At this time, a significantly reduced gene expression in MCS compared to 1g-controls was visible for IL6, IL8, FN1, ITGB1, LAMA1, CCL2, and TLN1. After a 72 h RPM-exposure, IL-6, IL-8, and TIMP-1 secretion rates were increased significantly. Conclusion: Normal thyrocytes form MCS within 24 h. Cytokines seem to be involved in the initiation of MCS formation via focal adhesion proteins.

show abstract

“…A great number of cytokines have been identified in humans, and their functions have been widely studied in animal models and human cells. Several cytokines have proved effective in the clinical treatment of specific diseases [3,4,5,6,7]. Understanding the molecular mechanism of cytokine function will help us better examine and treat different disease conditions.…”

Section: Introductionmentioning

confidence: 99%

Regulation of Memory T Cells by Interleukin-23

Wang²,

Lu³

et al. 2016

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Interleukin-23 (IL-23), a member of the IL-12 family of cytokines, is a heterodimeric cytokine. It is composed of subunits p40 (shared with IL-12) and p19 (an IL-12 p35-related subunit) and is secreted by several types of immune cells, such as natural killer cells and dendritic cells. The IL-23 receptor is composed of the subunit IL-12Rβ1 and the IL-23-specific subunit IL-23R. The binding of IL-23 to its specific cell surface receptor regulates a number of functions, including proliferation and differentiation of cells and secretion of cell factors. Memory T cells are a subset of T cells that secrete numerous important cell factors, and they function in the immune response to infection and diseases like cancer, autoimmune disease and bronchial asthma. IL-23R is expressed on the surface of memory T cells, which suggests that it can specifically regulate memory T cell function. IL-23 has been widely used as a clinical indicator in immune-related diseases and shows potential for use in disease treatment. Here we review the current progress in the study of the role of IL-23 in the regulation of memory T cells.

show abstract

Interleukin-7 and Interleukin-15 for Cancer

Cited by 39 publications

References 94 publications

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells

Cytokine Release and Focal Adhesion Proteins in Normal Thyroid Cells Cultured on the Random Positioning Machine

Regulation of Memory T Cells by Interleukin-23

Contact Info

Product

Resources

About